Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer’s COVID-19 pill reduced risk of hospitalization or death by 89%

The pill could set a new bar for efficacy for an oral antiviral.

By Brian Buntz | November 5, 2021

PfizerPfizer (NYSE:PFE) today announced that its oral antiviral cut the risk of hospitalization or death by 89% in an interim analysis of the Phase 2/3 EPIC-HR trial.

Until recently, there were no oral treatments against the novel coronavirus. Molnupiravir, an oral antiviral from Merck (NYSE:MRK) and Ridgeback Biotherapeutics, recently won approval in the United Kingdom and is poised to find use in other countries. Merck said molnupiravir led to an approximately 50% reduction in hospitalizations and deaths versus placebo.

The Pfizer EPIC-HR trial study found that 7% of the participants who received a placebo were later hospitalized or died. However, only 0.8% of patients who received Paxlovid were hospitalized within 28 days, and there were no deaths in the drug group.

The trial results “suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a news release.

Pfizer will stop enrollment in the study based on feedback from the independent Data Monitoring Committee and FDA. The company plans to file data from the trial with the FDA as part of its request for emergency use authorization.

In addition to its protection against serious COVID-19 infections, the drug appeared to be well tolerated. Some 19% of Paxlovid recipients had adverse events, lower than the 21% of placebo recipients did. The majority of the events were mild.

Paxlovid is a SARS-CoV-2-3CL protease inhibitor, while molnupiravir is a ribonucleoside analog.

PFE shares jumped 10.86% to $48.61, an all-time high for the stock. Meanwhile, MRK shares fell 9.86% to $81.61.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50